Home

Articles from ADMA Biologics, Inc.

ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update
FY 2024 Preliminary Unaudited Total Revenue of Approximately $417-425 Million, Exceeding Previous Guidance of $415 Million
By ADMA Biologics, Inc. · Via GlobeNewswire · January 13, 2025
ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025
RAMSEY, N.J. and BOCA RATON, Fla., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that Company management will present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, California, January 13-16, 2025. ADMA’s presentation will be on Monday, January 13, 2025, at 10:30 a.m. PT.
By ADMA Biologics, Inc. · Via GlobeNewswire · January 7, 2025
ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility
Cash on Hand Utilized to Repay $30 Million of Senior Secured Term Loan Facility to Ares Capital
By ADMA Biologics, Inc. · Via GlobeNewswire · December 20, 2024
ADMA Biologics Announces Third Quarter 2024 Financial Results and Provides Business Update
3Q 2024 Total Revenue of $119.8 Million, a 78% Increase Y-o-Y
By ADMA Biologics, Inc. · Via GlobeNewswire · November 7, 2024
ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024
Conference Call Scheduled for November 7, 2024, at 4:30 p.m. ET
By ADMA Biologics, Inc. · Via GlobeNewswire · October 29, 2024
ADMA Biologics Set to Join S&P SmallCap 600 Index
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced it will join the S&P SmallCap 600 index, effective prior to the open of trading on Monday, September 23, 2024. The S&P SmallCap 600 seeks to measure the small-cap segment of the U.S. equity market.
By ADMA Biologics, Inc. · Via GlobeNewswire · September 17, 2024
ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference in New York, NY on September 17, 2024, at 3:05 p.m. ET.
By ADMA Biologics, Inc. · Via GlobeNewswire · September 10, 2024
ADMA Biologics Announces Partial Paydown of Revolving Credit Facility
Cash on Hand Utilized to Repay $30 Million of Revolving Credit Facility to Ares Capital with No Prepayment Penalties
By ADMA Biologics, Inc. · Via GlobeNewswire · August 14, 2024
ADMA Biologics Announces Second Quarter 2024 Financial Results and Provides Business Update
2Q 2024 Total Revenue of $107.2 Million, a 78% Increase Y-o-Y
By ADMA Biologics, Inc. · Via GlobeNewswire · August 8, 2024
ADMA Biologics to Report Second Quarter 2024 Financial Results on August 8, 2024
Conference Call Scheduled for August 8, 2024, at 4:30 p.m. ET
By ADMA Biologics, Inc. · Via GlobeNewswire · August 1, 2024
ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update
1Q 2024 Total Revenue of $81.9 Million, a 44% Increase Y-o-Y
By ADMA Biologics, Inc. · Via GlobeNewswire · May 9, 2024
ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024
Conference Call Scheduled for May 9, 2024, at 4:30 p.m. ET
By ADMA Biologics, Inc. · Via GlobeNewswire · May 2, 2024
ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®
FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf Life
By ADMA Biologics, Inc. · Via GlobeNewswire · March 11, 2024
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
RAMSEY, N.J. and BOCA RATON, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Raymond James Institutional Investor Conference on March 6, 2024, at 11:35 a.m. ET.
By ADMA Biologics, Inc. · Via GlobeNewswire · March 5, 2024
ADMA Biologics Announces CFO Transition
Executive Search Initiated for CFO Replacement
By ADMA Biologics, Inc. · Via GlobeNewswire · February 28, 2024
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4Q 2023 Total Revenue of $73.9 Million; FY 2023 Total Revenue of $258.2 Million
By ADMA Biologics, Inc. · Via GlobeNewswire · February 28, 2024
ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Conference Call Scheduled for February 28, 2024, at 4:30 p.m. ET
By ADMA Biologics, Inc. · Via GlobeNewswire · February 21, 2024
ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics
ADMAlytics Combines Generative AI and Machine Learning to Optimize Production Processes
By ADMA Biologics, Inc. · Via GlobeNewswire · February 21, 2024
ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update
4Q 2023 Preliminary Unaudited Total Revenue of $72-74 Million
By ADMA Biologics, Inc. · Via GlobeNewswire · January 8, 2024
ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management
New $135 Million Credit Facility Replaces Existing $159 Million Credit Facility, a 15% Decrease in Total Debt
By ADMA Biologics, Inc. · Via GlobeNewswire · December 18, 2023
ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age and Older
Signifies the Successful Fulfillment of BIVIGAM’s Post Marketing Commitments as Part of the Original BLA Approval
By ADMA Biologics, Inc. · Via GlobeNewswire · December 12, 2023
ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD
FDA Approval Signifies the Accomplishment of ADMA’s Corporate Goal of Plasma Supply Self-Sufficiency
By ADMA Biologics, Inc. · Via GlobeNewswire · November 16, 2023
ADMA Biologics Announces Third Quarter 2023 Financial Results and Provides Business Update
3Q2023 Total Revenues of $67.3 Million, a 64% Y-o-Y Increase
By ADMA Biologics, Inc. · Via GlobeNewswire · November 8, 2023
ADMA Biologics to Report Third Quarter 2023 Financial Results on November 8, 2023
Conference Call Scheduled for November 8, 2023, at 4:30 p.m. ET
By ADMA Biologics, Inc. · Via GlobeNewswire · November 1, 2023
ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update
2Q2023 Total Revenues of $60.1 Million, a 77% Y-o-Y Increase
By ADMA Biologics, Inc. · Via GlobeNewswire · August 9, 2023
ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023
Conference Call Scheduled for August 9, 2023, at 4:30 p.m. ET
By ADMA Biologics, Inc. · Via GlobeNewswire · August 2, 2023
ADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA
FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth
By ADMA Biologics, Inc. · Via GlobeNewswire · July 19, 2023
ADMA Biologics Announces First Quarter 2023 Financial Results and Provides Business Update
1Q2023 Total Revenues of $57 Million, a 96% Y-o-Y Increase
By ADMA Biologics, Inc. · Via GlobeNewswire · May 10, 2023
ADMA Biologics to Report First Quarter 2023 Financial Results on May 10, 2023
Conference Call Scheduled for May 10, 2023, at 4:30 p.m. ET
By ADMA Biologics, Inc. · Via GlobeNewswire · May 3, 2023
ADMA Biologics Announces Amendment to Credit Agreement
Reduces Nominal Interest Rate by 1%
By ADMA Biologics, Inc. · Via GlobeNewswire · May 2, 2023
ADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
4Q2022 Total Revenues of $50 Million, a 90% Y-o-Y Increase
By ADMA Biologics, Inc. · Via GlobeNewswire · March 23, 2023
ADMA Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023
Conference Call Scheduled for March 23, 2023, at 4:30 p.m. ET
By ADMA Biologics, Inc. · Via GlobeNewswire · March 16, 2023
ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA
FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth
By ADMA Biologics, Inc. · Via GlobeNewswire · February 8, 2023
ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Provides 2023 Financial Guidance
Fourth Quarter 2022 Preliminary Unaudited Total Revenues of Approximately $49-$50 Million, an 89% Year-Over-Year Increase
By ADMA Biologics, Inc. · Via GlobeNewswire · January 17, 2023
ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM®
FDA approvals for both ASCENIV and BIVIGAM provide for room temperature (25°C) storage conditions for up to 4 weeks during the first 24 months of the 36-month approved shelf life
By ADMA Biologics, Inc. · Via GlobeNewswire · December 13, 2022
ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 09, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the closing of its previously announced underwritten public offering of 20,979,020 shares of its common stock at a public offering price of $2.86 per share, in addition to the exercise in full of the underwriters’ option to purchase an additional 3,146,853 shares of common stock. The gross proceeds from the exercise of the overallotment option were $9 million, bringing the total gross proceeds to ADMA from the offering to $69 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
By ADMA Biologics, Inc. · Via GlobeNewswire · December 9, 2022
ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today priced its previously announced underwritten public offering of 20,979,020 shares of its common stock at a public offering price of $2.86 per share, resulting in gross proceeds of approximately $60 million before deducting underwriting discounts and commissions and other estimated offering expenses.
By ADMA Biologics, Inc. · Via GlobeNewswire · December 7, 2022
ADMA Biologics Announces Proposed Public Offering of Common Stock
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it intends to offer shares of its common stock for sale in an underwritten public offering. The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  
By ADMA Biologics, Inc. · Via GlobeNewswire · December 6, 2022
ADMA Biologics Announces Preliminary Fourth Quarter 2022 Revenue Estimate
Fourth Quarter 2022 Preliminary Estimated Total Revenues of Approximately $48-$50 Million
By ADMA Biologics, Inc. · Via GlobeNewswire · December 6, 2022
ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business Update
3Q2022 Total Revenues Were $41.1 Million, a 99% Y-o-Y Increase
By ADMA Biologics, Inc. · Via GlobeNewswire · November 9, 2022
ADMA Biologics to Report Third Quarter 2022 Financial Results on November 9, 2022
Conference Call Scheduled for November 9, 2022, at 4:30 p.m. ET
By ADMA Biologics, Inc. · Via GlobeNewswire · November 2, 2022
ADMA BioCenters Receives FDA Approval for its Seventh Plasma Collection Center, Located in Greensboro, NC
FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth
By ADMA Biologics, Inc. · Via GlobeNewswire · October 31, 2022